Guillermo Chantada/LinkedIn
May 8, 2025, 13:52
Guillermo Chantada: From 66% to 83% in 20 years – Improvement in OS in Burkitt lymphoma in Argentina
Guillermo Chantada, President of the International Society of Paediatric Oncology (SIOP), shared a post on LinkedIn:
“From 66% to 83% in 20 years!
Another pearl from the ROHA (National Pediatric Cancer Registry in Argentina) is the improvement in overall survival in Burkitt lymphoma over the years.There was a major leap in the past five years and my explanation is that this is because of the use of a regimen pioneered at the Hospital Garrahan in 2008 when I was there, that used a reduced dose of methotrexate (in a 4 hours infusion instead of 24hs) in combination with Rituximab for high risk cases.
There reason why I think this is because the slope of the K-M curve showing that the mortality in the first year flattened compared to the previous years when more chemotherapy intensive regimens were used.
It may be argued that improvements in supportive care in general may explain this phenomenon, but this has not been observed in ALL for example which shows the same survival results and shape of the K-M curve in the same interval. The percentage of patients treated in referral centers is the same for BL as in ALL.
Choosing the right treatment matters, designing treatments according to the type of our events matters and also the support of institutions like Hospital Garrahan at that time when rituximab was not approved in high income countries for Burkitt lymphoma is critical.”
Learn more about Burkitt lymphoma on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 19:09
May 29, 2025, 17:58
May 29, 2025, 17:45
May 29, 2025, 17:39